Vaccination of cancer patients with tumor-specific antigens, and biology of cytokines

Informations projet

TUMOR VACCINES, CYTO

N° de convention de subvention: QLG1-CT-2000-60013

Projet clôturé

Date de début 21 Janvier 2002

Date de fin 20 Janvier 2006

Financé au titre de

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Coût total € 480 000,00

Contribution de l’UE € 480 000,00

Coordonné par

CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY
Belgium

Objectif

Our groups work on the characterization of human tumour-specific antigens recognized by T lymphocytes, the use of these antigens for therapeutic vaccination of cancer patients, and the biology of new cytokines.

Champ scientifique

• medical and health sciences › clinical medicine › oncology

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Thème(s)

• 1.1.1.-7. - Chronic and degenerative diseases, cancer, diabetes, cardivascular diseases and rare diseases

Appel à propositions

Data not available

Régime de financement

BUR - Bursaries, grants, fellowships

Coordinateur

CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY

• Contribution de l’UE: Aucune donnée
• Adresse: Avenue Hippocrate 74 ; 1200 BRUXELLES ; Belgique
• Coût total: Aucune donnée